Prevea Health

Recent papers from Prevea Health

1. Cost-Effectiveness Analysis of Ribociclib plus an Aromatase Inhibitor (AI) Versus AI Alone in the Adjuvant Treatment of Stage II and III Pre- and Postmenopausal Women with HR+/HER2− Early Breast Cancer (EBC): A Canadian Payer PerspectivePharmacoEconomics - Open · 2026
2. Residual Disparities in US Adults Hospitalized due to All-Cause Pneumonia Following Implementation of Childhood 13-Valent Pneumococcal Conjugate Vaccine in National Immunization ProgramOpen Forum Infectious Diseases · 2026
3. Defining and modeling ‘cure’ in early-stage melanoma: perspectives from a systematic literature reviewFrontiers in Oncology · 2026
4. Residual Disparities in US Children Hospitalized Due to All-Cause Pneumonia Following Implementation of Childhood PCV13 in National Immunization ProgramVaccines · 2026
5. Diagnostic delays, treatment timeliness, and patient experiences in triple-negative breast cancer: a mixed-methods studyFrontiers in Oncology · 2026
6. Cost-effectiveness of RSVpreF for the prevention of respiratory syncytial virus illness among high-risk adults in GermanyExpert Review of Vaccines · 2026
7. Persistence Among Biologic/JAKi-Naive Medicare Beneficiaries with RA Initiating Synthetic DMARDsRheumatology and Therapy · 2026
8. Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the NetherlandsInfectious Diseases and Therapy · 2026
9. Characterizing and quantifying disease impacts of generalized myasthenia gravis (gMG) in the United States: insights from patient and caregiver interviews and surveysJournal of Patient-Reported Outcomes · 2026
10. Budget Impact of Strategies Involving RSVpreF and Nirsevimab to Protect Infants in Saudi Arabia Against Respiratory Syncytial VirusInfectious Diseases and Therapy · 2026
11. Financial and Mental Health Burden on Caregivers of Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States (P3-1.007)Neurology · 2026
12. Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysisJournal of Comparative Effectiveness Research · 2026
13. Expenditures attributable to infant lower respiratory tract infection due to respiratory syncytial virus in the US: A real-world study using the PharMetrics Plus Database, 2015–2023Human Vaccines & Immunotherapeutics · 2026
14. Importance of where you die: Lung cancer mortality trends in homeless-proxy settings across the U.S.Journal of Clinical Oncology · 2026
15. Net costs associated with inpatient (IP) administration of step-up dosing (SUD) of bispecific antibodies (bsAbs) among Medicare patients (pts) with relapsed/refractory multiple myeloma (MM).Journal of Clinical Oncology · 2026
16. Treatment strategies and survival outcomes in hepatic epithelioid hemangioendothelioma: A systematic review.Journal of Clinical Oncology · 2026
17. Temporal trends and disparities in sudden cardiac death among pancreatic cancer patients in the United States.Journal of Clinical Oncology · 2026
18. Early deviations from guideline-concordant care in triple-negative breast cancer: A patient-reported analysis.Journal of Clinical Oncology · 2026
19. Multilevel disparities in HIV-associated gastrointestinal cancer mortality in the United States, 1999–2020.Journal of Clinical Oncology · 2026
20. Sociodemographic and geographic disparities in early-onset pancreatic cancer mortality in the United States, 1999–2020.Journal of Clinical Oncology · 2026